Literature DB >> 31092692

A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates.

Sung-Youl Ko1, Wataru Akahata1, Eun Sung Yang1, Wing-Pui Kong1, Crystal W Burke2, Shelley P Honnold3, Donald K Nichols3, Yan-Jang S Huang4, Gretchen L Schieber1, Kevin Carlton1, Luis DaSilva5, Vicki Traina-Dorge6, Dana L Vanlandingham4, Yaroslav Tsybovsky7, Tyler Stephens7, Ulrich Baxa7, Stephen Higgs4, Chad J Roy6, Pamela J Glass2, John R Mascola8, Gary J Nabel8, Srinivas S Rao8.   

Abstract

Western, Eastern, and Venezuelan equine encephalitis viruses (WEEV, EEEV, and VEEV, respectively) are important mosquito-borne agents that pose public health and bioterrorism threats. Despite considerable advances in understanding alphavirus replication, there are currently no available effective vaccines or antiviral treatments against these highly lethal pathogens. To develop a potential countermeasure for viral encephalitis, we generated a trivalent, or three-component, EEV vaccine composed of virus-like particles (VLPs). Monovalent VLPs elicited neutralizing antibody responses and protected mice and nonhuman primates (NHPs) against homologous challenges, but they were not cross-protective. In contrast, NHPs immunized with trivalent VLPs were completely protected against aerosol challenge by each of these three EEVs. Passive transfer of IgG from immunized NHPs protected mice against aerosolized EEV challenge, demonstrating that the mechanism of protection was humoral. Because they are replication incompetent, these trivalent VLPs represent a potentially safe and effective vaccine that can protect against diverse encephalitis viruses.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31092692     DOI: 10.1126/scitranslmed.aav3113

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  14 in total

1.  Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress.

Authors:  Lauren E Williamson; Kristen M Reeder; Kevin Bailey; Minh H Tran; Vicky Roy; Mallorie E Fouch; Nurgun Kose; Andrew Trivette; Rachel S Nargi; Emma S Winkler; Arthur S Kim; Christopher Gainza; Jessica Rodriguez; Erica Armstrong; Rachel E Sutton; Joseph Reidy; Robert H Carnahan; W Hayes McDonald; Clara T Schoeder; William B Klimstra; Edgar Davidson; Benjamin J Doranz; Galit Alter; Jens Meiler; Kevin L Schey; Justin G Julander; Michael S Diamond; James E Crowe
Journal:  Cell       Date:  2021-08-19       Impact factor: 66.850

2.  Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.

Authors:  Emily E Coates; Srilatha Edupuganti; Grace L Chen; Myra Happe; Larisa Strom; Alicia Widge; Maria Burgos Florez; Josephine H Cox; Ingelise Gordon; Sarah Plummer; Abidemi Ola; Galina Yamshchikov; Charla Andrews; Sharon Curate-Ingram; Patricia Morgan; Shashi Nagar; Matthew H Collins; Amy Bray; Thuy Nguyen; Judy Stein; Christopher L Case; Florence Kaltovich; Diane Wycuff; C Jason Liang; Kevin Carlton; Sandra Vazquez; John R Mascola; Julie E Ledgerwood
Journal:  Lancet Infect Dis       Date:  2022-05-11       Impact factor: 71.421

3.  Long-term persistence of viral RNA and inflammation in the CNS of macaques exposed to aerosolized Venezuelan equine encephalitis virus.

Authors:  Henry Ma; Joseph R Albe; Theron Gilliland; Cynthia M McMillen; Christina L Gardner; Devin A Boyles; Emily L Cottle; Matthew D Dunn; Jeneveve D Lundy; Noah Salama; Katherine J O'Malley; Ivona Pandrea; Tobias Teichert; Stacey Barrick; William B Klimstra; Amy L Hartman; Douglas S Reed
Journal:  PLoS Pathog       Date:  2022-06-13       Impact factor: 7.464

Review 4.  Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.

Authors:  Lampouguin Yenkoidiok-Douti; Christopher M Jewell
Journal:  ACS Biomater Sci Eng       Date:  2020-01-12

Review 5.  Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape.

Authors:  Anthony Torres-Ruesta; Rhonda Sin-Ling Chee; Lisa F P Ng
Journal:  Microorganisms       Date:  2021-04-22

6.  Neutralizing antibodies protect mice against Venezuelan equine encephalitis virus aerosol challenge.

Authors:  Natasha M Kafai; Lauren E Williamson; Elad Binshtein; Soila Sukupolvi-Petty; Christina L Gardner; Jaclyn Liu; Samantha Mackin; Arthur S Kim; Nurgun Kose; Robert H Carnahan; Ana Jung; Lindsay Droit; Douglas S Reed; Scott A Handley; William B Klimstra; James E Crowe; Michael S Diamond
Journal:  J Exp Med       Date:  2022-03-17       Impact factor: 17.579

Review 7.  Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.

Authors:  Jesús Zepeda-Cervantes; Josué Orlando Ramírez-Jarquín; Luis Vaca
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

8.  Synthesis and biological activity of conformationally restricted indole-based inhibitors of neurotropic alphavirus replication: Generation of a three-dimensional pharmacophore.

Authors:  Scott J Barraza; Janice A Sindac; Craig J Dobry; Philip C Delekta; Pil H Lee; David J Miller; Scott D Larsen
Journal:  Bioorg Med Chem Lett       Date:  2021-06-15       Impact factor: 2.940

9.  Complete Coding Sequence of Western Equine Encephalitis Virus Strain Fleming, Isolated from a Human Case.

Authors:  Crystal W Burke; Michael R Wiley; Brett F Beitzel; Christina L Gardner; Yan-Jang Huang; Ashley E Piper; Dana L Vanlandingham; Stephen Higgs; Gustavo Palacios; Pamela J Glass
Journal:  Microbiol Resour Announc       Date:  2020-01-02

10.  The Western Equine Encephalitis Lyophilized, Inactivated Vaccine: An Update on Safety and Immunogenicity.

Authors:  Maryam Keshtkar-Jahromi; Ronald B Reisler; Jeannine M Haller; Denise P Clizbe; Robert G Rivard; Anthony P Cardile; Benjamin C Pierson; Sarah Norris; David Saunders; Phillip R Pittman
Journal:  Front Immunol       Date:  2020-11-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.